Physician profile
Eric B Stone
NPI 1114917218
$2,159.49
in general payments reported to CMS, 2019-2025
26 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $290 · 2021: $294 · 2023: $143 · 2024: $426 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.53 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $302.92 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $287.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $259.45 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $156.43 | 2019-2024 | Glassia, Trintellix |
| Abbvie INC. | $147.22 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $134.84 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $121.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $109.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.86 | 2020-2025 | Jardiance |
| Pfizer INC. | $88.06 | 2021-2025 | |
| Amgen INC. | $85.72 | 2019-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $63.33 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.33 | 2019 | |
| Axsome Therapeutics, INC. | $31.88 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $29.47 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $27.89 | 2019-2020 | |
| Shockwave Medical, INC | $25.39 | 2025 | |
| Organon LLC | $23.24 | 2023 | Nexplanon |
| Gilead Sciences, INC. | $21.76 | 2025 | |
| Dexcom, INC. | $18.62 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $17.36 | 2019 | |
| Merck Sharp & Dohme LLC | $17.08 | 2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Astellas Pharma US INC | $16.94 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.88 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $13.99 | 2019 | |
| Mylan Specialty L.P. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.